Drug Profile
Research programme: proteome-based therapeutics - Vividion Therapeutics
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Vividion Therapeutics
- Class Anti-inflammatories; Antineoplastics; Neuroprotectants; Small molecules
- Mechanism of Action Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation; Neurodegenerative disorders
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Inflammation in USA
- 28 Apr 2022 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
- 28 Apr 2021 No recent reports of development identified for research development in Cancer in USA